Please Note: The Conference Program below is not in its final version, adjustments will occur. Final Program will be available two months before the conference date.

BIT's 3rd International Congress of Antibodies-2011

(ICA-2011)

Theme: Discovery, Partnering to Market

Time: March 23-25, 2011 Venue: China National Convention Center, Beijing, China

Scientific Program Group Photo Time: 08:30, March 23, 2011 Place: E1 Entrance, CNCC Opening Ceremony Time: 09:00-09:15, March 23, 2011 Place: Room No. 311A, 3rd Floor, CNCC Keynote Forum Moderator Dr. Dexian Zheng, Professor, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, China 09:15-09:45 Title: From Donor Derived Antibody Phage Libraries to Antibody Repertoire Analysis to Synthetic Library Design - Coming Full Circle in Our Efforts to Understand and Recapitulate Functional Diversity of Antibodies Dr. Arvind Rajpal, Senior Director, Rinat - Pfizer Inc., USA（Present for Dr. Jaume Pons） 09:45-10:15 Title: Early CMC-activities in Therapeutic Antibody Development Dr. Ralf Ostendorp, Vice President, Protein Sciences, MorphoSys AG, Germany 10:15-10:45 Title: Winds of Change in Biotech: Do We Need a Better Windmill or a Different Climate Dr. Paul Chapman, Head of Biopharm Process Solutions, EMD Millipore, USA 10:45-11:15 Title: Use of Blocking Antibodies for Treatment of Sepsis Dr. Peter A. Ward, Stobbe Professor of Pathology, Department of Pathology, University of Michigan Health Systems, USA 11:15-11:45 Title: A Comprehensive Toolkit to Accelerate Antibody Development Dr. NingNing Ma, VP, Process Development, Sino Biological Inc., China 18:00-20:30 Welcome Banquet

Scientific Program Opening Ceremony & Keynote Forum - Discovery, Partnering to Market Track 1: Breaking Researches of Antibodies -From Discovery to Tech Innovations Track 2: Researches on Antibody Molecular Targets of Diseases -Targeting Antibody Therapeutics Discovery Track 3: Therapeutic Monoclonal Antibodies R &D -From Early to Late Stage Track 4: Medical and Agricultural Applications of Antibodies -From Diagnostics to Practice Track 5: Research Applications of Antibodies -Antibody as Powerful Research Tools Track 6: Antibody Design, Engineering and Production -Accelerating Antibody Industrialization Track 7: Workshops and Training Courses - Learning and Enhancing Career and Business Development Young Scientist Forum

Track 1: Breaking Researches of Antibodies- From Discovery to Tech Innovations  

Track 1-1: Immune System and Immunology of Antibodies, and Functions Time: 13:30-15:10, March 23, 2011 (Wednesday) Place: Room No. 209A, 2nd Floor, CNCC

Chair: Dr. Paul Imbach, Professor, University Children's Hospital Basel, Switzerland 13:30-13:50 Keynote Speech: Title: Biologic Immunotherapeutics in Autoimmune Disorders Dr. Paul Imbach, Professor, University Children's Hospital Basel, Switzerland 13:50-14:10 Title: Cellular Network Modeling: The Conundrum of Developing Immune Systems Dr. Wilfried Allaerts, Editor-in-chief, Biological Publishing A&O, The Netherlands 14:10-14:30 Title: Have We Overestimated the Benefit of Human(ized) Antibodies Dr. Daniel R Getts, Head of Research and Development, Tolera Therapeutics Inc., USA 14:30-14:50 Title: Antibody-based Cancer Immunotherapy: From Cytotoxicity to Immunomodulation Dr. Rolando Pérez, Vice President & Deputy General Manager, Biotech Pharmaceutical Ltd., China 14:50-15:10 Title: Computer Aided Diagnosis; The Issue of Skewed Data Dr. Paolo Soda, Lecturer, Medical Informatics & Computer Science Laboratory, University Campus Bio-Medico of Rome, Italy 15:10-15:30 Coffee Break

Track 1-2: Phage Display and Other Directed Molecular Evolution Technologies Time: 15:30-17:35, March 23, 2011 (Wednesday) Place: Room No. 209A, 2nd Floor, CNCC

Chair: Dr. Pascale Mathonet, Team Leader, Isogenica Ltd., UK 15:30-15:55 Title: Protein and Peptide Discovery Using CIS Display Dr. Pascale Mathonet, Team Leader, Isogenica Ltd., UK 15:55-16:20 Title: The PURE Ribosome Display Method: Selection of Protein Probes Using the Reconstituted Cell-free Translation Systems Dr. Takuya Ueda, Professor, University of Tokyo, Japan 16:20-16:45 Title: Antigen Identification by Phage Display Dr. André Frenzel, Lecturer, Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Germany 16:45-17:10 Title: Development of Next-generation Ribosome Display Technologies Dr. Akira Wada, Senior Research Scientist, Advanced Science Institute, RIKEN, Japan 17:10-17:35 Title: mRNA-display Selection of Single Chain Fv against CD44 Dr. Noriko Tabata, Research Fellow, Keio University, Japan

Track 1-3: Proteomics, Epitomics and Antibody Mimetics for Antibody Discovery Time: 08:30-09:45, March 24, 2011 (Thursday) Place: Room No. 208A, 2nd Floor, CNCC

Chair: Dr. Jenny Ottosson, Director, Department of Proteomics, School of Biotechnology, KTH - Royal Institute of Technology, Sweden 08:30-08:55 Title: Antibody Generation within the Human Protein Atlas Project Dr. Jenny Ottosson, Director, Department of Proteomics, School of Biotechnology, KTH - Royal Institute of Technology, Sweden 08:55-09:20 Title: The Binding Modes of Sequence-based Epitope and Paratope Mimetics: Real or Imaginary Mimicry Dr. Danièle Altschuh, Principal Investigator, Biosensor Group, IREBS, CNRS - University of Strasbourg, France 09:20-09:45 Title: The Evaluation of Antibody Responses to Rabies Virus Using Retroviral Pseudotypes and the Implications for 'In-field' Vaccine Trials Dr. Kestutis Suziedelis, Head of Laboratory of Molecular Oncology, Institute of Oncology of Vilnius University, Lithuania

Track 1-4: Immunotoxins and Antibodies Time: 10:30-12:10, March 24, 2011 (Thursday) Place: Room No. 208A, 2nd Floor, CNCC

Chair: Dr. África González-Fernández, Full Professor, University of Vigo, Spain 10:30-10:55 Title: Nanoparticles and Antibodies: A Complex Alliance Dr. África González-Fernández, Full Professor, University of Vigo, Spain 10:55-11:20 Title: Antibody Formation to Type A Botulinum Toxin: Clinical Implications and the State of the Art Dr. Daniel Sutphin, Chief Resident, Department of Plastic Surgery, University of Tennessee College of Medicine/ Chattanooga Unit, USA 11:20-11:45 Title: NanoMAb®: 3rd Generation Antibody Therapeutics Dr. S.Y. Seong, Professor, Department of Biomedical Sciences, Seoul National University College of Medicine, South Korea 11:45-12:10 Title: Evaluation of Antibodies in Human Brucelllosis Dr. Annapurna S. Agasthya, Professor, Department of Biotechnology, Lovely Professional University, India

Track 1-5: Antiphospholipid Antibody and Systemic Autoimmune Diseases Time: 13:30-15:10, March 24, 2011 (Thursday) Place: Room No. 208B, 2nd Floor, CNCC

Chair: Dr. Katarzyna Fischer, Head, Laboratory of Department of Rheumatology and Internal Diseases, Pomeranian Medical University of Szczecin, Poland 13:30-13:55 Title: Autoimmune Hemolytic Anemia Caused by Elevated Oxidative Stress in Red Blood Cell Dr. Yoshihito Iuchi, Associate Professor, Yamaguchi University, Japan 13:55-14:20 Title: Antiphospholipid Antibodies and Early Atherosclerotic Changes in Patients with Systemic Lupus Erythematosus Dr. Katarzyna Fischer, Head, Laboratory of Department of Rheumatology and Internal Diseases, Pomeranian Medical University of Szczecin, Poland 14:20-14:45 Title: Anticardiolipin Antibodies in Jamaican Women: The Relationship with Thromboembolic Disorders and Pregnancy Dr. Eulalia Kahwa, Lecturer, The UWI School of Nursing, Mona, University of the West Indies, Jamaica 14:45-15:10 Title: Abdominal Manifestations of Antiphospholipid Syndrome Dr. Neziha Belkahla, Gastroenterologist, University Ernest Conseil Hospital - Tunis, Tunisia 15:10-15:30 Coffee Break

Track 1-6: Immunoglobulin Diversity and Antibodies Time: 15:30-17:30, March 24, 2011 (Thursday) Place: Room No. 208B, 2nd Floor, CNCC

Chair: Dr. Christopher J. Mann, Global Head, Application Support and Training, Genetix, UK Co-Chair: Dr. Xiaoying Zhang, Professor, Northwest Agricultural �� Forestry University, China 15:30-15:50 Title: A New Screening Platform for Antibodies against the Cell Surface Antigens of Intact Mammalian Cells Dr. Haiying Hang, Professor, Institute of Biophysics, Chinese Academy of Sciences, China 15:50-16:10 Title: Building a Model of Single-chain Variable Fragment (scFv) of IgY for the Production of Antivenom Dr. Wilmar Dias da Silva, Professor, Immunochemistry Laboratory, Butantan Institute, Brazil 16:10-16:30 Title: mIgY, A Novel Antibody Research Platform Dr. Xiaoying Zhang, Professor, Northwest Agricultural �� Forestry University, China 16:30-16:50 Title: Targets of Somatic Hypermutation within Immunoglobulin Genes in Zebrafish Dr. Anastasia M. Zimmerman, Assistant Professor, College of Charleston, USA 16:50-17:10 Title: Low Levels of IgM Antibodies to Oxidized Cardiolipin Increase but High Levels Decrease Risk of Cardiovascular Disease in 60-year Olds from Stockholm County Dr. Jun Su, Department of Medicine, Karolinska University Hospital, Sweden 17:10-17:30 Title: Wobbling over Mother Nature: How to Construct the True Single Antigen Discriminative Antibodies Dr. Katarzyna A Lechward, Eu Flippases Consortium, Poland

Track 1-7: Nanosensors, Microarray, Biochips and Cytokine Antibody Arrays Time:10:30-12:10, March 25, 2011 (Friday) Place: Room No. 208B, 2nd Floor, CNCC

Chair: Dr. Volker Stadler, CEO, PEPperPRINT GmbH, Germany Co-Chair: Dr. Peter Nilsson, Associate Professor, Department of Proteomics, School of Biotechnology, KTH - Royal Institute of Technology, Sweden 10:30-10:50 Title: Custom Peptide Microarrays for Comprehensive Antibody and Serum Analysis Dr. Volker Stadler, CEO, PEPperPRINT GmbH, Germany 10:50-11:10 Title: A High-throughput, Flexible Microfluidic Platform for Large Scale Epitope Mapping and Other Proteomics Applications Dr. Xiaolian Gao, CSO, LC Sciences, USA 11:10-11:30 Title: Systematic Antigen-array Based Proteomic Profiling Dr. Peter Nilsson, Associate Professor, Department of Proteomics, School of Biotechnology, KTH – Royal Institute of Technology, Sweden 11:30-11:50 Title: A Novel Platform Technology for Protein Chips Based on the 9G DNA Chip and 9G Membrane System Dr. Taisun Kim, Professor, Department of Chemistry, Hallym University, Korea 11:50-12:10 Title: UCL Miniaturized and Low Cost Innovative Detection Systems for Medical and Environmental Applications Dr. Luis Moreno Hagelsieb, Researcher, Université Catholique de Louvain, Belgium

Track 1-8: Autoantibodies, Autoimmunity and Implications in Discovery and Diagnosis Time:10:30-12:10, March 25, 2011 (Friday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Mark Zimering, Associate Professor, Department of Veterans Affairs, New Jersey Health Care System, USA Co-Chair: Dr. Adriaan M. Duijvestijn, Associate Professor, Maastricht University, The Netherlands 10:30-10:50 Title: Spontaneous Antibodies Inhibit Fibroblast Growth Factor: Role in Diabetic Vascular Complications Dr. Mark Zimering, Associate Professor, Department of Veterans Affairs, New Jersey Health Care System, USA 10:50-11:10 Title: An Evaluation of a Novel Assay for the Detection of Anti-SSA Antibodies Dr. Richard Steele, Clinical Immunologist, Department of Immunology, Wellington Hospital, New Zealand 11:10-11:30 Title: Prevalence and Functional Heterogeneity of Anti-endothelial Cell Antibodies (AECA) in Vascular Disease Dr. Adriaan M. Duijvestijn, Associate Professor, Maastricht University, The Netherlands 11:30-11:50 Title: Antinuclear Antibody Its Significance on Autoimmune Liver Diseases and Clinical Problems Dr. Mikio Zeniya, Professor, Jikei University Graduate School of Medicine, Japan 11:50-12:10 Title: Catalytic Antibodies as Molecular Tools in the Neurodegeneration and Demyelination Dr. Sergey Suchkov, Professor in Clinical Immunology, I.M. Sechenov Moscow Medical Academy & Moscow State Medical and Dentistry University, Russia Presenter: Dr. Leonid Martynov, I.M. Sechenov Moscow Medical Academy and Moscow State Medical & Dentistry University, Russia

Track 1-9: Antibody Characterization Technologies and Structure Biology Time:08:30-12:35, March 25, 2011 (Friday) Place: Room No. 209A, 2nd Floor, CNCC

Chair: Dr. Rajendra Singh, Director, Biology R&D, Caliper Lifesciences, USA Co-Chair: Dr. Kenneth H. Roux, Professor, Florida State University, USA 08:30-08:55 Title: Enzymatic Modification of IgG - Novel Tools for F(ab')2 Generation & Deglycosylation of IgG Dr. Sarah Fredriksson, CEO, Genovis AB, Sweden 08:55-09:20 Title: Microfluidic Electrophoresis Assays for Antibody and Protein Biotherapeutic Characterization Dr. Rajendra Singh, Director, Biology R&D, Caliper Lifesciences, USA 09:20-09:45 Title: Structure and Function Studies of a Therapeutic Antibody Dr. Yung-Hsiang Kao, Senior Scientist, Protein Analytical Chemistry, Genentech, Inc., USA 09:45-10:10 Title: Methods for Epitope Mapping Using Monoclonal Antibodies Dr. Kenneth H. Roux, Professor, Florida State University, USA 10:10-10:30 Coffee Break 10:30-10:55 Title: Structural and Functional Characterization of a Dual-action Fab Recognizing EGFR and HER3 Dr. Charles Eigenbrot, Senior Scientist, Genentech Inc., USA 10:55-11:20 Title: Developing Novel Mass Spectrometric Tools to Identify Post-translational Modifications and Sequence Variants of Antibody Therapeutics Dr. Jennifer Zhang, Scientist, Protein Analytical Chemistry, Genentech Inc., USA 11:20-11:45 Title: A Platform for Systematic Validation of Antibody Specificity Using siRNA Dr. Charlotte Stadler, Science for Life Laboratory, Sweden 11:45-12:10 Title: Characterization of an Antibody against the Serotonin Receptor 1A by a Gel-based Proteomics Method----A Recommendation How to Unambiguously Characterise an Antibody Dr. Lin Li, Proteomics Lab Manager, Medical University of Vienna, Austria 12:10-12:35 Title: Early Identification of Left Ventricular Dysfunction with Speckle Tracking Echocardiography in Antineoplastic Therapy with the ErbB2-antibody Trastuzumab Dr. Nicola Maurea, Chief, Division of Cardiology, National Cancer Institute, G Pascale Foundation, Italy

Track 1-10: Generation of Immune and Synthetic Libraries, and High Throughput Screening Time: 13:30-14:45, March 25, 2011 (Friday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Zoltán Konthur, Group Leader, Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Germany 13:30-13:55 Title: Generation of Recombinant Antibodies as Tools in Functional Genomics Dr. Zoltán Konthur, Group Leader, Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Germany 13:55-14:20 Title: Phage Display Derived Antibodies for Proteomics, Diagnostics and Therapy Dr. Michael Hust, Group Leader, Technische Universität Braunschweig, Institut für Biochemie und Biotechnologie, Germany 14:20-14:45 Title: RiceAb V2.0 - A Pilot Program Towards Generate Antibodies Against Each Rice Proteins Dr. Guozhen Liu, Vice President, Beijing Protein Innovation Co., Ltd, China

Track 1-11: Transgenic Animals and Plants Time: 13:30-14:20, March 25, 2011 (Friday) Place: Room No. 212A, 2nd Floor, CNCC

Chair: Dr. Larry L. Green, CEO, Ablexis, LLC, USA 13:30-13:55 Title: Transgenic Mouse Platforms for Successful Human Therapeutic Antibody Discovery and Development Dr. Larry L. Green, CEO, Ablexis, LLC, USA 13:55-14:20 Title: Towards a Transgenic Platform for Generating High-affinity Human Single-domain Antibody Therapeutics Dr. Mike Romanos, CEO, Crescendo Biologics Ltd, UK

Track 2: Researches on Antibody Molecular Targets of Diseases -Targeting Antibody Therapeutics Discovery 
 

Track 2-1: Transmembrane Receptor, Ion Channels and Cytokine Targets Time: 15:30-17:35, March 23, 2011 (Wednesday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Wenle Xia, Director, Oncology Research Laboratory, Duke University Medical Center, USA 15:30-15:50 Title: Antibodies Targeting Death Receptors for Cancer Therapy Dr. Dexian Zheng, Professor, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, China 15:50-16:10 Title: The New Era of ErbB2 Target Therapy Dr. Wenle Xia, Director, Oncology Research Laboratory, Duke University Medical Center, USA 16:10-16:30 Title: Epidermal Growth Factor Receptor Variants as Cancer Therapeutic Target Dr. Zonghai Li, Professor, Shanghai Cancer Institute, China 16:30-16:50 Title: FGF/FGFR Pathway and Its Targeting in Renal Cell Carcinoma Dr. Ilya Tsimafeyeu, Director, Kidney Cancer Research Bureau, Russia 16:50-17:10 Title: Dissecting Ligand Specific Severn Trans-membrane Receptor Signaling Complexes Dr. Jinpeng Sun, Professor, School of Medicine, Shandong University, China 17:10-17:35 Title: Transient Receptor Potential Channel M5 - Expressing Chemosensory Cells in Mouse Nasal Cavity Dr. Weihong Lin, Assistant Professor, University of Maryland, Baltimore County, USA

Track 2-2: Cytokine and Cell Adhesion Molecule Targets Time: 08:30-09:45, March 25, 2011 (Friday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Dan Jia, Assistant Professor, Department of Radiation Oncology, University of Arkansas for Medical Sciences, USA 08:30-08:55 Title: Anti-hyaluronan Antibodies: New Challenges, New Opportunities Dr. Rafael Mañez, Director of Critical Care Medicine, Bellvitge University Hospital, Spain 08:55-09:20 Title: Targeting the Bone to Prevent Severe Side Effects After Non-skeleton Focal Radiotherapy Dr. Dan Jia, Assistant Professor, Department of Radiation Oncology, University of Arkansas for Medical Sciences, USA 09:20-09:45 Title: Cytokines and Chemokines as Therapeutic Targets in Renal Diseases Dr. Frederick Wai Keung Tam, Senior Clinical Lecturer, Imperial College London, UK

Track 3:Therapeutic Monoclonal Antibodies R & D -From Early to Late Stage 

Track 3-1: Antibodies Targeting Breast Cancer Time: 15:30-17:35, March 23, 2011 (Wednesday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Mary E. Edgerton, Associate Professor, Department of Pathology, University of Texas M.D. Anderson Cancer Center, USA Co-Chair: Dr. Le Sun, President, AbMax Biotechnology, Inc., China 15:30-15:55 Title: Anticipated Antibodies of Clinical Interest in the Treatment of Breast Cancer Dr. Mary E. Edgerton, Associate Professor, Department of Pathology, University of Texas M.D. Anderson Cancer Center, USA 15:55-16:20 Title: Do the ASCO/CAP 2007 HER2 Testing Guidelines Accurately Identify Patients Who Will Benefit from Adjuvant Trastuzumab Dr. Beiyun Chen, Associate Professor, Mayo Clinic Rochester, USA 16:20-16:45 Title: Monoclonal Antibody-drug Immunoconjugates for Cancer Treatments Dr. Le Sun, President, AbMax Biotechnology, Inc., China 16:45-17:10 Title: Kinetics on Cells - Bridging the Gap between Traditional Biosensor and Cell Based Assay Dr. Samuel Altun, Cell Application Researcher, Attana AB, Sweden 17:10-17:35 Title: Circulating Epithelial Tumor Cells, An Unparalelled Tool for Repeated and Continuous Monotoring of Disease in Solid Cancers Dr. Katharina Pachmann, Professor, Department for Experimental Haematology und Oncology, Clinic for Internal Medicine II, Friedrich Schiller University Jena, Germany

Track 3-2: MAbs against Cardiovascular, Musculoskeletal and Thyroid Diseases Time: 15:30-17:10, March 23, 2011 (Wednesday) Place: Room No. 210B, 2nd Floor, CNCC

Chair: Dr. Beatrix Volc-Platzer, Head, Department of Dermatology, Donauspital - Affiliated Hospital with the University of Vienna, Austria 15:30-15:55 Title: New Treatment Strategies for Dermatomyositis Dr. Beatrix Volc-Platzer, Head, Department of Dermatology, Donauspital - Affiliated Hospital with the University of Vienna, Austria 15:55-16:20 Title: Increased Prevalence of Vulnerable Atherosclerotic Plaques but not General Atherosclerosis in SLE: Association with Age, Hyperlipidemia and Negatively, With Natural IgM Antibodies against Phosphorylcholine Dr. Xiang Hua, Physician, Department of Medicine, Karolinska University Hospital, Sweden 16:20-16:45 Title: Monoclonal Antibodies and Cardiovascular Diseases Dr. M.Hakan Terekeci, Assistant Professor, Division of Internal Medicine, GATA Haydarpasa Training Hospital, Turkey 16:45-17:10 Title: Monoclonal Antibodies and Thyroid Diseases Dr. Mesut Tiglioglu, Division of Internal Medicine, GATA Haydarpasa Training Hospital, Turkey

Track 3-3: Antibodies for Parkinson's Disease, Multiple Sclerosis and Alzheimer's Disease Time: 08:30-11:20, March 24, 2011 (Thursday) Place: Room No. 208B, 2nd Floor, CNCC

Chair: Dr. Michael Parker, Deputy Director, St Vincents Institute of Medical Research, Australia Co-Chair: Dr. Scott K. Dessain, Associate Professor, Lankenau Institute for Medical Research, USA 08:30-08:55 Title:Novel Antibody Therapy Approach in Multiple Sclerosis Targeting Immunopathogenic Protein from Endogenous Retroviral Element while Preserving Host's Immune System Dr. Alois B. Lang, Chief Development Officer, Geneuro SA, Switzerland 08:55-09:20 Title: Structural Biology of Anti-alzheimer's Antibodies Dr. Michael Parker, Deputy Director, St Vincents Institute of Medical Research, Australia 09:20-09:45 Title: Candidate Human Monoclonal Antibody Therapeutics for Alzheimer's Disease Dr. Scott K. Dessain, Associate Professor, Lankenau Institute for Medical Research, USA 09:45-10:10 Title: Affibody Molecules in Therapy Applications: Targeting Cancer and Alzheimer's Disease Dr. Stefan Stahl, Research Leader, Division of Molecular Biotechnology, Royal Institute of Technology (KTH), Sweden 10:10-10:30 Coffee Break 10:30-10:55 Title: Anti Alpha-synuclein Intrabody Has Potential Therapy for Parkinson's Disease Dr. Jiro Fukae, Neurologist, Juntendo University School of Medicine, Japan 10:55-11:20 Title: Development of Monoclonal Antibodies for the Diagnosis and Treatment of Senile Dementia (Alzheimer's Disease) Dr. Ying Zhang, Lecturer, College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, China

Track 3-4: MAbs against Rheumatoid Arthritis, Asthma, Psoriasis and Inflammatory Bowel Disease Time: 08:30-12:35, March 24, 2011 (Thursday) Place: Room No. 209A, 2nd Floor, CNCC

Chair: Dr. George Spencer-Green, Clinical Head of the Immunology/Rheumatology Program in Small Molecules, Vertex Pharmaceuticals, Inc., USA Co-Chair: Dr. Katherine Li, Senior Research Scientist, Centocor R&D, Inc., USA 08:30-08:55 Title: Antibody Treatment in Rheumatic Diseases: Where Have We Come from? Where Are We now? Where Are We Going? Dr. George Spencer-Green, Clinical Head of the Immunology/Rheumatology Program in Small Molecules, Vertex Pharmaceuticals, Inc., USA 08:55-09:20 Title: Determining the Extent to which Clinically Effective Treatment, Ustekinumab or Etanercept, Reverses the Molecular Disease Profile of Psoriatic Skin: Comparisons of Lesional, Non-lesional and Normal Skin Dr. Katherine Li, Senior Research Scientist, Centocor R&D, Inc., USA 09:20-09:45 Title: Anti-citrulline Antibody as Novel Therapeutic Drug in early Rheumatoid Arthritis Dr. Jos Raats, President and CEO, ModiQuest B.V., The Netherlands 09:45-10:10 Title: Targeting the IgE Pathway for the Treatment of Asthma Dr. Lawren Wu, Scientist, Department of Immunology, Genentech, Inc., USA 10:10-10:30 Coffee Break 10:30-10:55 Title: Efficacy of an Anti-IL-6R Ab against Chronic Inflammatory Disease, RA, JIA, IBD and AA Amyloidosis Dr. Kazuyuki Yoshizaki, Professor, Center for Advanced Science and Innovation, Osaka University, Japan 10:55-11:20 Title: Targeting the α1 Integrin as Potential Therapy for Immune Mediated Arthritis Dr. Ilan Bank, Deputy Director, Department of Medicine F, Sheba Medical Center, Israel 11:20-11:45 Title: Is There any Future for Biological Treatments in Less Common Rheumatic Diseases? Dr. Coziana Ciurtin, Consultant in Rheumatology, Lister Hospital, UK 11:45-12:10 Title: Is Remission in Rheumatoid Arthritis during Anti-TNF Treatment a Real Thing? Dr. Ileana Filipescu, Assistant Professor, Department of Rheumatology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Romania 12:10-12:35 Title: Il-20 Antibody is a Potential Drug for Rheumatoid Arthritis Dr. Ming-shi Chang, Distinguished Professor, Department of Biochemistry and Molecular Biology, Medical College of National Cheng-kung University, Taiwan

Track 3-5: Biomarkers in Antibody Clinical Trials Time: 10:30-12:10, March 24, 2011 (Thursday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Daniel Sikkema, Executive Director, BioPharm R&D, GlaxoSmithKline, USA 10:30-10:55 Title: The Evaluation of Target-engaged Biomarkers in BioPharm R&D Dr. Daniel Sikkema, Executive Director, BioPharm R&D, GlaxoSmithKline, USA 10: 55-11:20 Title: Current Practice: Clinical Immunogenicity Assessments for Biotherapeutics Dr. Catherine Wang, Manager, Clinical Immunology, Biopharm R&D, GlaxoSmithKline, USA 11:20-11:45 Title: Immunoassay Validation: New Approach for Biomarkers in Pre-clinical and Clinical Studies Dr. Marie-Anne Valentin, Head of Immunoassay Development Lab, Novartis Pharma AG, Switzerland 11:45-12:10 Title: An Update in the Therapeutic Antibody Development in Clinical Oncology Dr. Weiqiang (John) Zhao, Interim Director, Pathology Core Facility, Human Tissue Resource Network, Department of Pathology, OSU Medical Center and James Cancer Center, USA

Track 3-6: Antigen Design, Antibody Generation and Functional Screen Time: 13:30-17:10, March 24, 2011 (Thursday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Leodevico (Vic) L. Ilag, Scientific Advisor, Prima BioMed Ltd, Australia Co-Chair: Dr. Jiewei Wei, CEO, Australian Biobest Biotechnology Service, Australia 13:30-13:55 Title: Stable Expression of Recombinant Human Glycoprotein in CHO Cells Dr. Jiewei Wei, CEO, Australian Biobest Biotechnology Service, Australia 13:55-14:20 Title: Development of Therapeutic CRIPTO-1 Antibodies to Treat Cancer Dr. Leodevico (Vic) L. Ilag, Scientific Advisor, Prima BioMed Ltd, Australia 14:20-14:45 Title: Engineering Camelid Single Domain Antibodies and Other Antibodies with FASEBA Platform Dr. Jianbing Oliver Zhang, Vice President, Antibody Drug Development Section, GenScript USA Inc., China 14:45-15:10 Title: Building up Technology Platforms to Screen for High Quality mAbs Against Cell Membrane Proteins Dr. Donghui Ma, Director of Immunology, OriGene Technologies Inc, USA 15:10-15:30 Coffee Break 15:30-15:55 Title: Development of Therapeutic Monoclonal Antibodies: Design, Engineering and Production Dr. Walter Low, Director of Technology Development and Antibody Engineering, PX'Therapeutics, France 15:55-16:20 Title: The SIMPLE AntibodyTM Platform: Transforming Discovery & Development of Human Monoclonal Antibodies Dr. Hans de Haard, Chief Scientific Officer, arGEN-X, Belgium 16:20-16:45 Title: Rapid Generation and Screening of Fully Human Monoclonal Antibodies and Antibody Fragments Using a Novel Platform Dr. Yan Chen, Vice President, X-BODY Biosciences, USA 16:45-17:10 Title: Creation of an Antibody-based Subcellular Protein Atlas Dr. Emma Lundberg, Senior Researcher, Science for Life Laboratory, Sweden

Track 3-7: Therapeutic Antibodies for Anti Severe Bacterial and Parasite Infection and STDs Time: 15:30-17:30, March 24, 2011 (Thursday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Alan Ebringer, Professor of Immunology, King's College London, UK Co-Chair: Dr. Timothy J. Pelura, President & CEO, Immunome, Inc, USA 15:30-15:50 Title: Antibodies in Ankylosing Spondylitis and Rheumatoid Arthritis Dr. Alan Ebringer, Professor of Immunology, King's College London, UK 15: 50-16:10 Title: Novel Native Human Monoclonal Antibodies (N-huMAbs) for Serious Infectious Disease Dr. Timothy J. Pelura, President & CEO, Immunome, Inc, USA 16:10-16:30 Title:Immune Globulin Y (Chicken Immune Globulin, Igy) an Alternative to Antibiotics to Fight Infections and Control Antibiotic Resistance Dr. Hans Kollberg, Professor, Cystic Fibrosis Centre, Uppsala University Childrens Hospital, Sweden 16:30-16:50 Title: Detecting of N.caninum and T. gondii Antibodies in Different Groups of Animals Dr. Eva Bartova, Assistant Professor, University of Veterinary and Pharmaceutical Sciences, Czech Republic 16:50-17:10 Title: Affinity is a Key Determinant for the Therapeutic Potential of Nanobodies against African Trypanosomiasis Dr. Guy Caljon, Postdoctoral Research Fellow, Institute of Tropical Medicine Antwerp, Belgium 17:10-17:30 Title: EMY162 Protein: Immuno Defense to Reduce Level of Alveolar Hydatid Disease Dr. Yoshinobu Katoh, Senior Researcher, Hokkaido Institute of Public Health, Japan

Track 3-8: Targeting Hematologic, Gastrointestinal, Colorectal, Brain Cancers and Lymphoma Time: 13:30-17:10, March 24, 2011 (Thursday) Place: Room No. 210B, 2nd Floor, CNCC

Chair: Dr. Ferdinand Bach, CEO, Oncoscience AG, Germany Co-Chair: Dr. Chris Garrett, Associate Professor, The University of Texas MD Anderson Cancer Center, USA 13:30-13:55 Title: Nimotuzumab (Theraloc®) in the Treatment of Children and Adults High Malignant Brain Tumors Dr. Ferdinand Bach, CEO, Oncoscience AG, Germany 13:55-14:20 Title: Integration of Monoclonal Antibodies into the Management of Colorectal Cancer: Will What We Have Learned Help Guide Us in the Future? Dr. Chris Garrett, Associate Professor, The University of Texas MD Anderson Cancer Center, USA 14:20-14:45 Title: Algorithmic Diagnostic Approach by Flow Cytometric Method for Hematological Malignancies Dr. Mohammad-Reza Sheikholeslami, Senior Hematopathologist, Nichols Institute/Quest Diagnostics, USA 14:45-15:10 Title: Retargeted NK92 for Anti-melanoma Activity by a TCR-like One Domain Antibody Dr. Bin Gao, Professor, The Centre for Molecular Immunology Institute of Microbiology, Chinese Academy of Sciences, China 15:10-15:30 Coffee Break 15:30-15:55 Title: Targeting GAG Binding Protein Domains: A Novel Approach for Cancer Therapy Dr. Avner Yayon, CEO, ProCore Ltd., Israel 15:55-16:20 Title: Molecular Targeting and Imaging of Gastric Cancer Metastasis Dr. Hayao Nakanishi, Section Head, Division of Oncological Pathology, Aichi Cancer Center Research Institute, Japan 16:20-16:45 Title: Anti-EGFR in Treatment of Metastatic Colorectal Cancer (mCRC) Dr. Kakil Ibrahim Rasul, Senior Consultant Physician, Al-Amal Hospital, Qatar 16:45-17:10 Title: Addition of Fresh Frozen Plasma to Rituximab: A Non-toxic Therapeutic Approach Capable of Inducing a Major Clinical and Laboratory Response in Patients with Advanced Treatment-refractory CLL Dr. Abraham Klepfish, Director, Blood Bank, E. Wolfson Medical Center, Israel

Track 3-9: Antibody Therapy in Solid Organ Transplantation Time: 08:30-10:10, March 25, 2011 (Friday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. David Basiji, CEO, Amnis Corporation, USA Co-Chair: Dr. Lionel Rostaing, Professor, Organ Transplant Unit, Toulouse University Hospital, France 08:30-08:55 Title: NFkB Rranslocation as a Quantitative Parameter for Clinical Immunosuppression Dr. David Basiji, CEO, Amnis Corporation, USA 08:55-09:20 Title: Successful Transplantation of Donor-specific Antibody Positive, Crossmatch Negative (AHG/FCXM) Renal Allograft Recipients Dr. Charles T. Van Buren, Professor, The University of Texas Medical School at Houston, USA 09:20-09:45 Title: Belatacept in Kidney Transplantation: Recent Data Dr. Lionel Rostaing, Professor, Organ Transplant Unit, Toulouse University Hospital, France 09:45-10:10 Title: The Association between Donor Specific Antibodies and Acute Rejection and Resolution in Small Bowel and Multivisceral Transplantation Dr. Hsin-Lin Tsai, Assistant Professor, National Yang-Ming University, Taiwan 10:10-10:30 Coffee Break

Track 3-10: Antibodies against Viral Infections Time: 10:30-12:35, March 25, 2011 (Friday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Marie-Anne Petit, Research Director, INSERM, France Co-Chair: Dr. Emmanuel Drouet, Professor in Virology, Faculty of Pharmacy, Grenoble University, France 10:30-10:55 Title: The Unique Monoclonal Antibody D32.10 Directed against the E1E2 Envelope Complexes of Serum Hepatitis C Virus as a New Drug Having Immunotherapeutic Potential Dr. Marie-Anne Petit, Research Director, INSERM, France 10:55-11:20 Title: Characterization of a Plant-produced MAb Therapeutic for West Nile Virus Dr. Qiang Chen, Professor, The Biodesign Institute, Arizona State University, USA 11:20-11:45 Title: Structure of the Fab Fragment from D32.10, A Monoclonal Antibody Specific for the Hepatitis C Virus E1E2 Envelope Antigen Dr. Emmanuel Drouet, Professor in Virology, Faculty of Pharmacy, Grenoble University, France 11:45-12:10 Title: B23680: An anti-HSV Fab Conjugate for Diagnostic Imaging Dr. Federico Maisano, Head of Biology, Bracco Imaging SPA, Italy 12:10-12:35 Title: Mumps Virus Deafness and Its Prevention by Vaccine-Japanese Present Conditions Dr. Satoshi Fukuda, Professor, Hokkaido University Hospital, Japan

Track 3-11: Antibody-Mediated Immunity and Infections Time: 13:30-15:10, March 25, 2011 (Friday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Stefan Magez, Research Professor, Free University of Brussels, Belgium 13:30-13:55 Title: Destruction of B-cell Memory Responses by Trypanosomes as Strategy to Evade Immune Recognition Dr. Stefan Magez, Research Professor, Free University of Brussels, Belgium 13:55-14:20 Title: The Immunoregulation of Cellular Response in Children with Helicobacter Pylori Dr. Elzbieta Czkwianianc, Professor, Faculty of Gastroenterology, Medical University of Lodz, Poland 14:20-14:45 Title: Use of Monoclonal Antibodies in the Design of Sensitive Diagnostic Assays and Therapeutics for Toxins Dr. Luisa W. Cheng, Research Biologist, U.S. Department of Agriculture, USA 14:45-15:10 Title: Antibodies against Plasmodium Falciparum Merozoite Surface Protein 1, A Potential Malaria Vaccine Dr. Roseangela Ifeyinwa Nwuba, Senior Lecturer, University of Ibadan, Nigeria

Track 3-12: Antibodies for Ovarian and Lung Cancer Time: 13:30-15:10, March 25, 2011 (Friday) Place: Room No. 210B, 2nd Floor, CNCC

Chair: Dr. T.-C. Wu, Professor, The Johns Hopkins University School of Medicine, USA 13:30-13:55 Title: Control of HPV-associated Cancer through Combined Treatment with Death Receptor 5-specific Antibody and Therapeutic HPV Vaccines Dr. T.-C. Wu, Professor, The Johns Hopkins University School of Medicine, USA 13:55-14:20 Title: Development of L-DOS47: An Antibody-enzyme Conjugate for Lung Cancer Application Dr.Baomin Tian, Senior Scientist, Helix BioPharma Corp., Canada 14:20-14:45 Title: Antibodies Against Non Small Lung Cancer Cells and Their Role in Diagnosis and Immunotherapy of Lung Cancer Dr. Giulio Tarro, Professor, Division of Infectious Diseases, D Cotugno Hospital, Italy 14:45-15:10 Title: Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis in Animal Models Dr. Min Zhu, Assistant Researcher, Department of Medcine/Division of Hemat-Onc, UCLA School of Medicine, USA 15:10-15:30 Coffee Break

Track 4: Medical and Agricultural Applications of Antibodies -From Diagnostics to Practice  

Track 4-1: Antigens, Polyclonal vs Monoclonal Antibodies Time: 13:30-15:10, March 23, 2011 (Wednesday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. James F. Cummings, Director, Walter Reed Army Institute of Research, USA 13:30-13:55 Title: Development of Standardized, Highly Reproducible ELISAs and Antibody Functional Assays at the WRAIR International Reference Center for Malaria Enzyme-linked Immunosorbent Assay Dr. James F. Cummings, Director, Walter Reed Army Institute of Research, USA 13:55-14:20 Title: Antibody Targeted Peptides in B-cell Leukemias: Overcoming Drug resistance, Biomarkers for Disease Relapse and Probes of Possible Disease Etiology Dr. Michael A Firer, Head, Department of Chemical Engineering, Biotechnology and Materials, Ariel University Center, Israel 14:20-14:45 Title: Site-directed in vitro Immunization Platform Provides a Suite of Pre-defined Specificities and Complete Human Molecules with Original Pairings as Illustrated by Human CTLA-4 Dr. Li-Te Chin, Senior Consultant, Abnova (Taiwan) Corporation, Taiwan 14:45-15:10 Title: Development of ELISA-based and xMAP-based Assays for Early Detection of Anthrax Protective Antigen Dr. Igor G. Shemyakin, Deputy Director, State Research Center for Applied Microbiology and Biotechnology, Russia

Track 4-2: Bispecific Biologics, Drug Conjugates and Imaging Time: 13:30-16:45, March 24, 2011 (Thursday) Place: Room No. 212A, 2nd Floor, CNCC

Chair: Dr. Jijie Gu, Principal Research Scientist, Abbott Bioresearch Center, USA Co-Chair: Dr. Wei Yan, Director of Research, Protein Science, Amgen Inc., USA 13:30-13:55 Title: Bi-and Multispecific Antibody Derivatives: Technologies and Applications in Virology and Oncology Dr. Ulrich Brinkmann, Scientific Director, Biologics Engineering, Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Germany 13:55-14:20 Title: Engineering of Asymmetrical Antibody Fusions Based on Fc Heterodimers Dr. Wei Yan, Director of Research, Protein Science, Amgen Inc., USA 14:20-14:45 Title: From Mono-therapy to Combination Therapy: The Biology and Therapeutic Potential of DVD-Ig Technology Dr. Jijie Gu, Principal Research Scientist, Abbott Bioresearch Center, USA 14:45-15:10 Title: Modular Antibodies: Introducing Antigen Binding Sites in the Fc Region of IgG Dr. Max Woisetschlãger, Director of Target Biology, f-star Biotechnologische Forschung Ges.m.b.H., Austria 15:10-15:30 Coffee Break 15:30-15:55 Title: Engineering of Anti-cadherin-11 Diabodies for ImmunoPET Imaging in Fibrosis Dr. John L. Xu, Senior Investigator I, China Novartis Institutes for BioMedical Research Co., Ltd., China 15:55-16:20 Title: Antibody Conjugated Microbubbles and Nanobubbles for Cancer Theranostics Dr. Ronald Xiaorong Xu, Assistant Professor, Department of Biomedical Engineering, The Ohio State University, USA 16:20-16:45 Title: Internalization of Quantum dots to Mesenchymal Stem Cells by Mortalin Antibody: Application to Cartilage Regeneration Dr. Tomokazu Yoshioka, Orthopaedics Surgeon, Department of Orthopaedic Surgery, Ibaraki Southwest Medical Center, Japan

Track 4-3: Biomarkers and Antibodies in Clinical Diagnostics Time: 08:30-09:45, March 25, 2011 (Friday) Place: Room No. 208B, 2nd Floor, CNCC

Chair: Dr. John L. Xu, Senior Investigator I, China Novartis Institutes for BioMedical Research Co., Ltd., China 08:30-08:55 Title: Trimannosyl-like Motif on Stem Cells and Carcinomas/inflamed Tissue Uniquely Recognized by Mannitou Antibody Dr. Birgit Zipser, Professor, Department of Physiology, Michigan State University, USA 08:55-09:20 Title: Integration of Translational Biomarkers in Clinical Trials for Biologics Dr. Weiping Shao, Associate Director, Bioanalytical Operations, Regeneron Pharmaceuticals, Inc., USA 09:20-09:45 Title: Immunohistochemical Evaluation of Xenografted Cat Ovaries Dr. Julianna Thuróczy, Associate Professor, Faculty of Veterinary Science, Szent István University, Hungary

Track 4-4: Mabs or Polyclonal Abs for Immunohistochemistry/Immunofluorescence Diagnosis Time: 15:30-17:10, March 25, 2011 (Friday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Pieter Demetter, Professor, Department of Pathology, Erasme University Hospital, Belgium 15:30-15:55 Title: Application of Immunohistochemistry to Neoplasms of the Digestive Tract Dr. Pieter Demetter,Professor, Department of Pathology, Erasme University Hospital, Belgium 15:55-16:20 Title: Abgent - The Primary Antibody Company Dr. Robert Huang, President, Abgent, Inc., USA 16:20-16:45 Title: Miniaturization of Immunoassay: Benefits, Limitations and Applications Dr. Mats Inganãs, Director of Applications & Technology Assessment, Gyros AB, Sweden 16:45-17:10 Title: Immunofluorescence Mapping for the Subtyping of Epidermolysis Bullosa - Practice and Pitfalls Dr.Wei X Melbourne, Hospital Scientist, University of New South Wales, Australia

Track 4-5: Biomarkers and Antibodies for Agricultural and Food Applications Time: 15:30-17:35, March 25, 2011 (Friday) Place: Room No. 212A, 2nd Floor, CNCC

Chair: Dr. Shridhar K. Sathe, Professor, Florida State University, USA Co-Chair: Dr. Laura K. Allred, Laboratory Director, ELISA Technologies, Inc., USA 15:30-15:55 Title: The Detection of Small Molecular Compounds in Agricultural Produce by Antibody Based Assays Dr. Titan S. Fan, President, Beacon Analytical Systems, Inc., USA 15:55-16:20 Title: Amandin as a Marker Protein for Almond (Prunus dulcis L.) Detection Dr. Shridhar K. Sathe, Professor, Florida State University, USA 16:20-16:45 Title: Speciation of Thermally-processed Meat and Feed Products Dr. Laura K. Allred, Laboratory Director, ELISA Technologies, Inc., USA 16:45-17:10 Title: Applying Antibodies for Food Safety Improvement Dr. Tung-Shi Huang, Associate Professor, Auburn University, USA 17:10-17:35 Title: Application of Immunotechnologies for Detection of Small Molecular Contaminants in Korean Foodstuffs Dr. Duck-Hwa Chung, Professor, Gyeongsang National University, Korea

Track 5: Research Applications of Antibodies -Antibody as Powerful Research Tools 

Track 5-1: Applications of Chimeric and Humanized Antibodies Time: 08:30-09:45, March 24, 2011 (Thursday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Walter Low, Director of Technology Development and Antibody Engineering, PX'Therapeutics, France 08:30-08:55 Keynote Speech Title: Protective Effects of mAB to IL-17A in Experimental Sepsis Dr. Peter A. Ward, Stobbe Professor of Pathology, Department of Pathology, University of Michigan Health Systems, USA 08:55-09:20 Title: Complement C5 Targeting in Atypical Hemolytic Uremic Syndrome : A Promising New Therapeutic Approach Dr. Anne Laure Lapeyraque, Pediatric Nephrologist, Sainte Justine Hospital, Canada 09:20-09:45 Title: Type Common Therapeutic Human Antibody against Herpes Simplex Viruses Dr. Jiann-Shiun Lai, Project Leader, Antibody Therapeutics, Department of Biologic Drugs, Development Center for Biotechnology, Taiwan

Track 5-2: Antibodies as Research Tools in Biomedical Research Time: 08:30-10:35, March 25, 2011 (Friday) Place: Room No. 210B, 2nd Floor, CNCC

Chair: Dr. Raj K. Tiwari, Professor, Department of Microbiology and Immunology, New York Medical College, USA 08:30-08:55 Title: Multi-parameter Signal Transduction Analyses of Normal Bone Marrow (BM) Subsets in Response to Cytokine/Growth Factor: Pre-requisite for Analysis of AML Abnormal Responses Dr. Charles Goolsby, Patterson Professor of Pathology, Northwestern University Feinberg School of Medicine, USA 08:55-09:20 Title: BD Biosciences' Family of Violet-excitable Dyes for Flow Cytometry Dr. Tim Dubrovsky, Senior Group Manager, Biological Research and Development, BD Biosciences, USA 09:20-09:45 Title: A Highly Fluorescent, Violet-excitable Dye for Cell Analysis Dr. Barny Abrams, Research Scientist, BD Biosciences, USA 09:45-10:10 Title: Synthetic Peptide Mimotopes as Cancer Antigens and Immunogenicity Prediction by Proteome Match Analysis Dr. Raj K. Tiwari, Professor, Department of Microbiology and Immunology, New York Medical College, USA 10:10-10:35 Title: Immobilization of Antibodies on Mesoporous Silica Materials and Their Binding Abilities to Antigens Dr. Katsuya Kato, Group Leader, National Institute of Advanced Industrial Science and Technology (AIST), Japan

Track 6: Antibody Design, Engineering and Production -Accelerating Antibody Industrialization 

Track 6-1: Cell Line and Model Organisms Development -Transgenic Animals, Transgenic Plants and High Yield Mammalian Cultures Time: 13:30-15:10, March 23, 2011 (Wednesday) Place: Room No. 209B, 2nd Floor, CNCC

Chair: Dr. Nicolas Mermod, Co-Founder, Selexis SA, Switzerland 13:30-13:55 Title: Engineered CHO Cells and Vectors for Fast and High-level Antibody Production Dr. Nicolas Mermod, Co-Founder, Selexis SA, Switzerland 13:55-14:20 Title: Application of Single Use Large Scale Bioreactors for Recombinant Protein Production Dr.Aziz Cayli, CEO, Cellca GmbH, Germany 14:20-14:45 Title: Automated High Throughput Cloning of CHO Cells and Hybridomas using Semi-solid Media Dr. Xiaoxi Chen, General Manager, Beijing Representative Office, STEMCELL Technologies Inc., Canada 14:45-15:10 Title: Purification Process Development of a Recombinant Monoclonal Antibody Expressed in Glycoengineered Pichia Pastoris Dr. Huijuan Li, Director of Glycoprotein Purification and Bioanalytics, GlycoFi, Inc., A Wholly Owned Subsidiary of Merck & Co., USA 15:10-15:30 Coffee Break

Track 6-2: Bioprocess Development for MAb Production and Modification Time: 08:30-12:35, March 24, 2011 (Thursday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Paul Chapman, Head of Biopharm Process Solutions, EMD Millipore, USA Co-Chair: Dr. Tibor Anderlei, Head of Science and Business Development, Adolf Kühner AG, Switzerland 08:30-08:55 Title: Rapid Scale-up from the Bench to the Patient-deploying Single-use Technologies for the Manufacture of Monoclonal Antibodies Dr. Paul Chapman, Head of Biopharm Process Solutions, EMD Millipore, USA Presenter: Dr. Steve Vermant, Head of Field Marketing - Asia Pacific, Biopharm Process Solution, Millipore(Shanghai) Trading Co.,Ltd, China 08:55-09:20 Title: "Factory of the Future" - Analysis of Upstream Intensification Using a Cost of Goods Model Dr. John Bonham-Carter, Vice President, Refine Technology, USA 09:20-09:45 Title: Manufacturing Considerations for Formulation Development Dr. Jun Liu, Senior Group Leader, Genentech, Inc., USA 09:45-10:10 Title: Efficient Identification and Isolation of Mammalian Cell Clones for MAb Production Dr. Christopher J. Mann, Senior Application Support Specialist, Genetix Ltd., UK 10:10-10:30 Coffee Break 10:30-10:55 Title: Cell Cultivation Scale up from 10mL to the 200L Using Shaken Disposable Bioreactors Dr. Tibor Anderlei, Head of Science and Business Development, Adolf Kühner AG, Switzerland 10:55-11:20 Title: From DNA to High-yield Antibody Production in CHO - The Fast Track Approach Dr. Florian M. Wurm, Professor of Biotechnology, Swiss Federal Institute of Technology, Switzerland 11:20-11:45 Title: Building a Facility with 100% Disposable Bioprocess Systems for MAb Production : Choices and Challenges Dr. Olivier Cochet, Director of Industrial Biotechnology, Institut de Recherche Pierre Fabre, France 11:45-12:10 Title: Next Generation MAb Facilities: Future Lifecycle Facility Design for Development and Production - Cost Effective Flexibility and Global Compliance Dr. Niels Guldager, Senior Consultant, NNE Pharmaplan, Denmark 12:10-12:35 Title: MSC-HCDC vs Fed-batch Culture in Monoclonal Antibody Production Technology Dr. Ho Nam Chang, Professor, KAIST(Korea Advanced Institute of Science and Technology), South Korea

Track 6-3: Improved Purification of Monoclonal Antibodies Time: 13:30-15:10, March 24, 2011 (Thursday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Larry J. Cummings, Consulting Scientist , Bio-Rad Laboratories, Inc., USA 13:30-13:55 Title: Monoclonal Antibody Purification Using a Multi-step Ion Exchange Process Dr. Larry J. Cummings, Consulting Scientist, Bio-Rad Laboratories, Inc., USA 13:55-14:20 Title: Purification and Characterization of Monoclonal Antibodies from Early Discovery to Lead Selection Dr. Haiyan Jiang, Principal Research Scientist, Biologics Research, Centocor R&D, Inc., USA 14:20-14:45 Title: Recent and Future Advances in Industrial Purification of Monoclonal Antibodies Dr. Hans J Johansson, Staff Scientist, GE Healthcare, Sweden 14:45-15:10 Title: Novel Approaches to Affinity Chromatography of Recombinant Antibodies Using SPR Imaging of Chemical Microarrays Dr. Thomas Neumann, Head of Screening, Graffinity Pharmaceuticals, Germany 15:10-15:30 Coffee Break

Track 7: Workshops and Training Courses -Learning and Enhancing Career and Business Development 

Workshop 1: Bio-Venture Capital Forum on Antibodies -Financing and Business Development Pharmaceutical Patents, Regulatory Considerations and Clinical Developments Case Studies: Strategic Alliances and Improvement on Existing Partnerships  Potentials of Outsourcing and Contract Manufacturing in Asia Biotech and Pharmaceutical Licensing, Deal-Making and Investment on mAB Effective Marketing Strategies and Distributions Time: 15:30-16:20, March 25, 2011 (Friday) Place: Room No. 210B, 2nd Floor, CNCC

Chair: Dr. Ben Goodger, Partner, Edwards Angell Palmer & Dodge UK LLP, UK 15:30-15:55 Title: New Investment and Financing Models for a Changing Pharma World Dr. Stephen Evans-Freke, General Managing Partner, Celtic Therapeutics, USA 15:55-16:20 Title: Biosimilars: An Overview of IP & Regulatory Issues and Recent Transactions Dr. Peter Lauro, Partner, Edwards Angell Palmer & Dodge, USA  Dr. Ben Goodger, Partner, Edwards Angell Palmer & Dodge UK LLP, UK

Young Scientist Forum Time: 15:30-17:35, March 25, 2011 (Friday) Place: Room No. 210A, 2nd Floor, CNCC

Chair: Dr. Willie Koh, Research Fellow, University College London, UK 15:30-15:55 Title: Use of Llama Antibody Fragments to Neutralize HIV Dr. Willie Koh, Research Fellow, University College London, UK 15:55-16:20 Title: Engineering Bispecificity into a Single Albumin-binding Domain Aimed for Drug Targeting and In Vivo Half-Life Extension Dr. Johan Nilvebrant, PhD-Student, Royal Institute of Technology, Sweden 16:20-16:45 Title: Evolving Application of Autoantibodies in the Field of Neuroimmunology Dr. Sharmilee Gnanapavan, Clinical Research Fellow, Institute of Neurology, UK 16:45-17:10 Title: New Monoclonal Antibodies against Helicobacter Pylori CagA Cytotoxin Dr. Alexander V. Klimovich, PhD Student, St.-Petersburg State University, Russia 17:10-17:35 Title: Polycystic Ovary Syndrome and Autoimmunity Dr. Jana Petrikova, Resident Doctor, Safarikiensis University, Slovakia